Targets › CNGA1
1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology.
Pore-forming subunit of the rod cyclic nucleotide-gated channel. Mediates rod photoresponses at dim light converting transient changes in intracellular cGMP levels into electrical signals. (UniProt, P29973)
Open in Phaseline: the race on CNGA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| VeonGen Therapeutics | VG901 AAV2-mediated gene therapy delivering functional CNGA1 gene | CNGA1 | Phase 1 | Retinitis Pigmentosa | – |
Retinitis Pigmentosa (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.